帕博利珠单抗用于广泛期小细胞肺癌患者:Ib期KEYNOTE-028研究结果
KEYNOTE-028是一项多队列、Ib期开放标签研究,评估帕博利珠单抗在PD-L1表达广泛期小细胞肺癌患者中的安全性和疗效。24例患者接受帕博利珠单抗10 mg/kg每2周一次治疗,客观缓解率为33%(95% CI,16%至55%),安全性与其他肿瘤类型已知安全性一致。
要点
- 24例PD-L1表达广泛期小细胞肺癌患者接受帕博利珠单抗治疗,客观缓解率为33%(95% CI,16%至55%)。
- 所有24例患者均发生不良事件,最常见为乏力(7例)、疲乏(7例)和咳嗽(6例)。
- 2例患者发生3至5级治疗相关不良事件:1例胆红素升高,1例乏力、5级结肠炎和肠缺血。
核心结论
- 帕博利珠单抗的安全性与其他肿瘤类型中已知的安全性特征一致。
- 帕博利珠单抗在经治的PD-L1表达小细胞肺癌患者中显示出有前景的抗肿瘤活性。
研究设计与样本
- 多队列、Ib期开放标签KEYNOTE-028研究(ClinicalTrials.gov标识符:NCT02054806)。
- 24例PD-L1表达广泛期小细胞肺癌患者入组并接受至少一剂帕博利珠单抗。
- 患者接受帕博利珠单抗10 mg/kg每2周一次,持续24个月或直至疾病进展或发生不可耐受的毒性。
- PD-L1表达通过免疫组织化学评估,PD-L1阳性定义为肿瘤及相关炎性细胞膜PD-L1表达≥1%或间质阳性染色。
- 主要终点为安全性、耐受性和客观缓解率;次要终点包括无进展生存期、总生存期和缓解持续时间。
主要发现
- 数据截止日期为2016年6月20日,中位随访时间为9.8个月(范围,0.5至24个月)。
- 所有24例患者均发生不良事件,最常见为乏力(n=7)、疲乏(n=7)和咳嗽(n=6)。
- 2例患者发生3至5级治疗相关不良事件:1例胆红素升高,1例乏力、5级结肠炎和肠缺血。
- 1例患者达到完全缓解,7例患者达到部分缓解,客观缓解率为33%(95% CI,16%至55%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The safety and efficacy of pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), were assessed in patients with programmed death ligand 1 (PD-L1)-expressing extensive-stage small-cell lung cancer (SCLC) in the multicohort, phase Ib open-label KEYNOTE-028 study ( ClinicalTrials.gov identifier: NCT02054806). Methods Patients with SCLC received pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity occurred. PD-L1 expression was assessed by immunohistochemistry. PD-L1-positive patients had membranous PD-L1 expression in ≥ 1% of tumor and associated inflammatory cells or positive staining in stroma. Response was assessed by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 every 8 weeks for the first 6 months and every 12 weeks thereafter. Adverse events (AEs) were reported per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Primary end points were safety, tolerability, and objective response rate (ORR). Secondary end points included progression-free survival, overall survival, and duration of response. Results Twenty-four patients with PD-L1-expressing SCLC were enrolled and received at least one pembrolizumab dose. At the data cutoff date (June 20, 2016), the median follow-up duration was 9.8 months (range, 0.5 to 24 months). All 24 patients experienced AEs; the most common were asthenia (n = 7), fatigue (n = 7), and cough (n = 6). Two patients experienced grade 3 to 5 treatment-related AEs: one patient had elevated bilirubin, and one patient had asthenia, grade 5 colitis, and intestinal ischemia. One patient had a complete response, and seven patients had partial responses, resulting in an ORR of 33% (95% CI, 16% to 55%). Conclusion The safety of pembrolizumab was consistent with the known safety profile in other tumor types. Pembrolizumab demonstrated promising antitumor activity in patients with pretreated, PD-L1-expressing SCLC.
引用
- Ott PA, Elez E, Hiret S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017. PMID: 28813164. doi:10.1200/JCO.2017.72.5069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。